• Explore /
  • Poster
  • / First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.

First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study.

Abstract Poster

Authors

Rui-Hua Xu

Rui-Hua Xu

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou, China

Rui-Hua Xu , Feng Wang , Junjie Peng , Xinjun Liang , Ying Cheng , Yanhong Deng , Kehe Chen , Mingjun Zhang , Jingdong Zhang , Wei Wang , Bangwei Cao , Yongdong Jin , Meili Sun , Yuan Lin , Su-Xia Luo , Zhen Li , Liu Yang , Qingyu Wang , Jing Li , Jun Zhu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04547166

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 124)

DOI

10.1200/JCO.2024.42.3_suppl.124

Abstract #

124

Poster Bd #

H9

Abstract Disclosures

Similar Posters

First Author: Nong Xu

First Author: Leora Horn

First Author: John Ebben

First Author: Kohei Shitara